Loading news...
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock.
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern.
Hussman Strategic Advisors Inc. increased its position in CorMedix Inc (NASDAQ: CRMD) by 400.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 315,000 shares of the company's stock after purchasing an additional 252,000 shares during the quarter. CorMedix makes up 0.8%
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.
CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.
New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential violations of the federal securities laws. On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026.
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.
Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn't sitting well with shareholders, primarily because CRMD's topline was roughly $400 million in the prior year, according to the preliminary full-year financials it posted on Thursday.
BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director.
‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒ Unaudited Cash and Short-term Investments of Approximately $148 million ‒ BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter 2025 and full-year 2025 results, and provides guidance and an update on its business.
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
An often overlooked risk for patients receiving dialysis for kidney failure or related conditions is infection. Unfortunately, infections among dialysis patients are both common and serious, presenting a significant complication and an unmet medical need.
BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company's ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care's (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters.
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
CRMD, CGAU, CMC, COMM and SHIP emerge as high earnings yield value picks as investors eye fundamentals ahead of key jobs and inflation reports.